{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:33:57Z","timestamp":1793151237520,"version":"4.5.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Metformin and liraglutide are used in the treatment of type 2 diabetes mellitus (T2DM) complicated with nonalcoholic fatty liver disease (NAFLD). Although these drugs can alter the intestinal microbiome, clinical data are required to explore their mechanisms of action. Using 16S sequencing technology, we analyzed and compared the intestinal bacterial community structure and function between patients before and after treatment (12\u2009weeks) with the two drugs (metformin or liraglutide, <jats:italic>n<\/jats:italic>\u2009=\u200915) and healthy controls (<jats:italic>n<\/jats:italic>\u2009=\u200915). Moreover, combined with 19 clinical indices, the potential therapeutic mechanisms of the two drugs were compared. The studied clinical indices included those associated with islet \u03b2-cell function (FPG, FINS, HbA1c, and HOMA-IR), inflammation (TNF-\u03b1, IL-6, and APN), lipid metabolism (TC, TG, and LDL-C), and liver function (ALT, AST, and GGT); the values of all indices changed significantly after treatment (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01). In addition, the effect of the two drugs on the intestinal bacterial community varied. Liraglutide treatment significantly increased the diversity and richness of the intestinal bacterial community (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05); it significantly increased the relative abundances of Bacteroidetes, Proteobacteria, and Bacilli, whereas metformin treatment significantly increased the relative abundance of Fusobacteria and Actinobacteria (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Metformin treatment increased the complexity and stability of the intestinal bacterial network. However, liraglutide treatment had a weaker effect on the intestinal bacterial network, and the network after treatment was similar to that in healthy controls. Correlation matrix analysis between dominant genera and clinical indicators showed that the correlation between the bacterial community and islet \u03b2-cell function was stronger after liraglutide treatment, whereas the correlation between the bacterial community and inflammation-related factors was stronger after metformin treatment. Functional prediction showed that liraglutide could significantly affect the abundance of functional genes related to T2DM and NAFLD (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05), but the effect of metformin was not significant. This study is the first to report the changes in the intestinal bacterial community in patients treated with metformin or liraglutide and the differences between the mechanisms of action of metformin and liraglutide. Metformin or liraglutide has a therapeutic value in T2DM complicated with NAFLD, with liraglutide having a weaker effect on the intestinal bacterial community but a better therapeutic efficacy.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1088187","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T07:26:46Z","timestamp":1674718006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Xing","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Rongjiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayila","family":"Kahaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Chunhui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhuyati","family":"Wulasihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.metabol.2018.10.004","article-title":"Adiponectin homolog novel osmotin protects obesity\/diabetes-induced NAFLD by upregulating AdipoRs\/PPAR\u03b1 signaling in Ob\/Ob and db\/db transgenic mouse models","volume":"90","author":"Ahmad","year":"2019","journal-title":"Metab. Clin. Exp."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nrgastro.2012.161","article-title":"The importance of the gut microbiota after bariatric surgery","volume":"9","author":"Aron-Wisnewsky","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of Nonalcoholic Fatty Liver Disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s13300-021-01033-x","article-title":"Efficacy and safety of Ertugliflozin in patients with type 2 diabetes inadequately controlled by metformin and sulfonylurea: a sub-study of VERTIS CV","volume":"12","author":"Budoff","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.chom.2014.11.010","article-title":"Diet dominates host genotype in shaping the murine gut microbiota","volume":"17","author":"Carmody","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41385-019-0162-4","article-title":"Emerging roles of bile acids in mucosal immunity and inflammation","volume":"12","author":"Chen","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"107180","DOI":"10.1016\/j.ecolind.2020.107180","article-title":"Rapid microbial community evolution in initial Carex litter decomposition stages in Bayinbuluk alpine wetland during the freeze\u2013thaw period","volume":"121","author":"Chen","year":"2021","journal-title":"Ecol. Indic."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"906168","DOI":"10.1155\/2014\/906168","article-title":"Systematic analysis of the association between gut flora and obesity through high-throughput sequencing and bioinformatics approaches","volume":"2014","author":"Chiu","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"760558","DOI":"10.3389\/fendo.2021.760558","article-title":"Editorial: the brain\u2013gut\u2013microbiome network in metabolic regulation and Dysregulation","volume":"12","author":"De Meyts","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J. Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/gutjnl-2020-322753","article-title":"Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function","volume":"70","author":"Frost","year":"2021","journal-title":"Gut"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11095-019-2753-x","article-title":"Metformin disrupts bile acid efflux by repressing bile salt export pump expression","volume":"37","author":"Garzel","year":"2020","journal-title":"Pharm. Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.chom.2021.09.007","article-title":"In vivo commensal control of Clostridioides difficile virulence","volume":"29","author":"Girinathan","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"CD012906","DOI":"10.1002\/14651858.CD012906.pub2","article-title":"Metformin monotherapy for adults with type 2 diabetes mellitus","volume":"2020","author":"Gnesin","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.3390\/ijms22073566","article-title":"The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-022-34671-1","article-title":"Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism","volume":"13","author":"Lei","year":"2022","journal-title":"Nat. Commun."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"eabk0855","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12986-020-00454-y","article-title":"Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis","volume":"17","author":"Li","year":"2020","journal-title":"Nutr. Metab."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1471-2407-12-155","article-title":"Inhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin Glargine up-titration vs insulin Degludec\/Liraglutide on Glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e3280","DOI":"10.1002\/dmrr.3280","article-title":"Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)","volume":"36","author":"Lipsky","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41579-018-0036-x","article-title":"Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier","volume":"16","author":"Martens","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S0029665120006916","article-title":"SCFA: mechanisms and functional importance in the gut","volume":"80","author":"Martin-Gallausiaux","year":"2021","journal-title":"Proc. Nutr. Soc."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jnutbio.2018.07.009","article-title":"Liraglutide modulates gut microbiota and reduces NAFLD in obese mice","volume":"62","author":"Moreira","year":"2018","journal-title":"J. Nutr. Biochem."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e2000375","DOI":"10.1002\/mnfr.202000375","article-title":"The gut microbiota and its metabolites, novel targets for treating and preventing non-alcoholic fatty liver disease","volume":"64","author":"Ni","year":"2020","journal-title":"Mol. Nutr. Food Res."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/mSystems.00115-21","article-title":"High-fiber, whole-food dietary intervention alters the human gut microbiome but not fecal short-chain fatty acids","volume":"6","author":"Oliver","year":"2021","journal-title":"mSystems"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fped.2020.00158","article-title":"Nonalcoholic fatty liver disease is associated with low skeletal muscle mass in overweight\/obese youths","volume":"8","author":"Pacifico","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.jlr.2021.100073","article-title":"The lipidome in nonalcoholic fatty liver disease: actionable targets","volume":"62","author":"Pirola","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet (London, England)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"106040","DOI":"10.1016\/j.ejps.2021.106040","article-title":"Dissolving microneedle-assisted long-acting Liraglutide delivery to control type 2 diabetes and obesity","volume":"167","author":"Rabiei","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s00125-013-2991-0","article-title":"Molecular mechanism of action of metformin: old or new insights?","volume":"56","author":"Rena","year":"2013","journal-title":"Diabetologia"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fmicb.2018.00061","article-title":"Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease","volume":"9","author":"Saltzman","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/0960327121999445","article-title":"Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT\/mTOR\/LC-3II pathways","volume":"40","author":"Seif El-Din","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"110785","DOI":"10.1016\/j.biopha.2020.110785","article-title":"The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling","volume":"131","author":"Shabalala","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/hep4.1284","article-title":"Gut microbial metabolism and nonalcoholic fatty liver disease","volume":"3","author":"Sharpton","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.chom.2020.01.021","article-title":"Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation","volume":"27","author":"Sinha","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dom.12748","article-title":"Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"109641","DOI":"10.1016\/j.celrep.2021.109641","article-title":"Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota","volume":"36","author":"Sun","year":"2021","journal-title":"Cell Rep."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"BSR20181304","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e02392","DOI":"10.1128\/mBio.02392-17","article-title":"Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial","volume":"9","author":"Tong","year":"2018","journal-title":"mBio"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3390\/nu12102982","article-title":"Gut microbiota in hypertension and atherosclerosis: a review","volume":"12","author":"Verhaar","year":"2020","journal-title":"Nutrients"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e00009","DOI":"10.1002\/edm2.9","article-title":"Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects","volume":"1","author":"Wang","year":"2017","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat. Med."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","article-title":"Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer","volume":"25","author":"Yachida","year":"2019","journal-title":"Nat. Med."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"906511","DOI":"10.3389\/fnut.2022.906511","article-title":"Effects of dietary nutrients on fatty liver disease associated with metabolic dysfunction (MAFLD): based on the intestinal-hepatic Axis","volume":"9","author":"Yao","year":"2022","journal-title":"Front. Nutr."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40168-022-01299-8","article-title":"Chicken jejunal microbiota improves growth performance by mitigating intestinal inflammation","volume":"10","author":"Zhang","year":"2022","journal-title":"Microbiome"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"5110276","DOI":"10.1155\/2021\/5110276","article-title":"Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications","volume":"2021","author":"Zhang","year":"2021","journal-title":"Mediators Inflamm."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2947549","DOI":"10.1155\/2020\/2947549","article-title":"Liraglutide attenuates nonalcoholic fatty liver disease by modulating gut microbiota in rats administered a high-fat diet","volume":"2020","author":"Zhang","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1440-1746.2009.06144.x","article-title":"Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people","volume":"25","author":"Zhou","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/nu13041244","article-title":"Short-chain fatty acids, maternal microbiota and metabolism in pregnancy","volume":"13","author":"Zi\u0119tek","year":"2021","journal-title":"Nutrients"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1088187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T07:26:49Z","timestamp":1674718009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1088187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":61,"alternative-id":["10.3389\/fmicb.2023.1088187"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1088187","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1088187"}}